Analytical Study of Antipsychotic Use in Schizophrenia Patients

Authors

  • Sinta wahyuni Department Farmasi Klinik,Fakultas Farmasi, Universitas Airlangga, Surabaya, Indonesia
  • Yulistiani Department Farmasi Klinik,Fakultas Farmasi, Universitas Airlangga, Surabaya, Indonesia.
  • Indra Zeth Department Farmasi Klinik
  • Josephine P Department Farmasi Klinik,Fakultas Farmasi, Universitas Airlangga, Surabaya, Indonesia

DOI:

https://doi.org/10.51601/ijhp.v6i2.650

Abstract

Background: Schizophrenia is a chronic mental disorder that affects thought processes, emotions, perceptions, and behavior. Antipsychotics are divided into first-generation (FGA) and second-generation (SGA) as the main therapy. Objective: To analyze the profile of antipsychotic use in hospitalized schizophrenia patients, including type, dose, route, frequency, and combination patterns. Methods: A retrospective observational study at Menur Mental Hospital Surabaya from July to September 2023 on 66 hospitalized schizophrenia patients. Data were analyzed descriptively. Results: The use of SGAs was more dominant than FGAs. The most common SGAs were clozapine 25 mg and risperidone 3 mg oral. The most common FGAs were trifluoperazine 5 mg and chlorpromazine 100 mg oral. The most common combination pattern was risperidone + clozapine. Conclusion: The pattern of antipsychotic use was dominated by the combination of risperidone and clozapine, reflecting the complexity of schizophrenia management that requires an individual approach.

Downloads

Download data is not yet available.

References

[1]. Agid, O., Foussias, G., & Remington, G. (2007). Second-generation antipsychotic drugs in the treatment of schizophrenia: A review. Psychiatric Clinics of North America, 30(2), 237-257.

[2]. Aggarwal, A., Khandelwal, A., Jain, M., & Jiloha, R. (2011). Breast enlargement associated with low dose olanzapine. Indian Journal of Pharmacology, 43(1), 87.

[3]. https://doi.org/10.4103/0253-7613.75681

[4]. D'Souza, R. S., & Hooten, W. M. (2023). Extrapyramidal Symptoms. In StatPearls.http://www.ncbi.nlm.nih.gov/pubmed/2887555

[5]. Hajam, YA, Rani, R., Ganie, SY, Sheikh, TA, Javaid, D., Qadri, SS, Pramodh, S., Alsulimani, A., Alkhanani, MF, Harakeh, S., Hussain, A., Haque, S., & Reshi, MS (2022). Oxidative Stress in Human Pathology and Aging: Molecular Mechanisms and Perspectives. Cells, 11(3), 552.https://doi.org/10.3390/cells11030552

[6]. Huhn, M., Nikolakopoulou, A., & Schneider-Thoma, J. (2019). Efficacy and safety of antipsychotic drugs for acute and maintenance treatment of schizophrenia. JAMA Psychiatry, 76(7), 705-712.

[7]. Kishimoto, T., Hagi, K., & Muench, J. (2019). Comparative effectiveness of second-generation antipsychotic drugs and antipsychotic polypharmacy in the treatment of schizophrenia. The Lancet Psychiatry, 6(1), 6-12.

[8]. Leucht, S., Correll, C. U., & Kahn, R. S. (2018). Management of schizophrenia: an update. Current Opinion in Psychiatry, 31(6), 449-455.

[9]. Muench, J., & Hamer, A. M. (2010). Adverse effects of antipsychotic medications. American Family Physician, 81(5), 617-622.

[10]. Olfson, M., Blanco, C., Wang, S., Laje, G., & Correll, C.U. (2014). National trends in mental health care among children, adolescents, and adults in the United States. JAMA Psychiatry, 71(1), 50-59.

[11]. Indonesian Association of Psychiatrists. (2011). Diagnostic and Statistical Guidelines for Mental Disorders (PDSKJI) III. Jakarta: PDSKJI.

[12]. Raypole, C. (2019). Understanding Extrapyramidal Symptoms and the Medications That Cause Them.https://www.healthline.com/health/symptom/extrapyramidal-symptoms

[13]. Stahl, S.M., Morrissette, D.A., Citrome, L., Saklad, S.R., Cummings, M.A., Meyer, J.M., O'day, J.A., Dardashti, L.J., & Warburton, K.D. (2021). “Meta-guidelines” for the management of patients with schizophrenia. CNS Spectrums, 18(3), 150–162.https://doi.org/10.1017/S109285291300014X

[14]. Seeman, M. V. (2012). Antipsychotic polypharmacy: A review of the literature and clinical implications. Journal of Clinical Psychiatry, 73(8), 1094-1100.

[15]. World Health Organization. (2021). World Mental Health Report: Transforming Mental Health for All. Geneva: World Health Organization.

[16]. Weng, J., Zhang, Y., Li, H., Shen, Y., & Yu, W. (2019). Study on risk factors of extrapyramidal symptoms induced by antipsychotics and its correlation with symptoms of schizophrenia. General Psychiatry, 32(1), e100026.https://doi.org/10.1136/gpsych-2018-100026

[17]. Zhang, K., Liao, P., Wen, J., & Hu, Z. (2022). Synaptic plasticity in schizophrenia pathophysiology. IBRO Neuroscience Reports, 13(October), 478–487. https://doi.org/10.1016/j.ibneur.2022.10.008.

Downloads

Published

2026-06-15

How to Cite

wahyuni, S., Yulistiani, Indra Zeth, & Josephine P. (2026). Analytical Study of Antipsychotic Use in Schizophrenia Patients. International Journal of Health and Pharmaceutical (IJHP), 6(2), 386–391. https://doi.org/10.51601/ijhp.v6i2.650

Issue

Vol. 6 No. 2 (2026): May 2026

Section

Articles

License

Copyright (c) 2026 Sinta wahyuni, Yulistiani, Indra Zeth, Josephine P

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.